A 52-year-old woman with a prosthetic mitral valve (mechanical, inserted 3 years ago) presents with fever, chills, and progressive fatigue for 2 weeks. She has been compliant with warfarin therapy (INR 2.5). On examination, temperature is 39.2°C, and a new systolic murmur is heard at the apex. Laboratory findings show hemoglobin 9.8 g/dL, WBC 12,500/μL, and ESR 78 mm/hr. Blood cultures are positive for Streptococcus bovis (now reclassified as Streptococcus gallolyticus). Transthoracic echocardiography shows a 14 mm vegetation on the prosthetic valve with mild paravalvular regurgitation. What is the most appropriate management?

Explanation

## Clinical Diagnosis **Key Point:** This patient has **prosthetic valve endocarditis (PVE)** caused by *Streptococcus gallolyticus* (formerly *S. bovis*), a viridans-group Streptococcus. PVE carries high mortality (up to 40%) and this patient has specific indications for surgical intervention. > **Clinical Pearl:** *S. gallolyticus* bacteremia/endocarditis is strongly associated with **colorectal carcinoma** — colonoscopy is mandatory after treatment to exclude GI malignancy (Harrison's Principles of Internal Medicine, 21st ed.). ## Early vs. Late PVE | Feature | Early PVE (< 60 days) | Late PVE (> 60 days) | |---------|----------------------|---------------------| | **Etiology** | *S. epidermidis*, *S. aureus*, GNB, fungi | Viridans Streptococci, Enterococcus, *S. aureus* | | **Pathogenesis** | Intraoperative contamination | Native valve-like hematogenous seeding | | **Prognosis** | Worse | Better, but still high mortality | This patient is **3 years post-implantation** → **Late PVE** with *S. gallolyticus*. ## Why Surgery Is Indicated Here Per **ESC 2023** and **AHA/ACC 2021** guidelines, surgical indications in PVE include: 1. **Paravalvular regurgitation** (present here) — indicates annular involvement, abscess formation, or valve dehiscence; cannot be corrected medically. 2. **Large vegetation (≥ 10 mm)** — this patient has a **14 mm vegetation**, conferring high embolic risk. 3. **Prosthetic material** — biofilm on mechanical valves renders antibiotics insufficient as monotherapy; mortality with antibiotics alone is 40–50% vs. 20–30% with surgery + antibiotics. **Surgical approach:** Prosthetic valve replacement + **4 weeks of IV antibiotics post-operatively** (total antibiotic course is typically 6 weeks from first negative blood culture, with at least 4 weeks post-surgery counted from the operative date). ## Antibiotic Regimen for Late PVE (Viridans Streptococcus) - **IV Penicillin G** 18–24 million units/day in divided doses OR **IV Ceftriaxone** 2 g Q24H - **Gentamicin** 3 mg/kg/day in divided doses (synergy for first 2 weeks) - **Duration:** 6 weeks total (always IV; oral therapy is **never** appropriate for PVE) ## Why Other Options Are Incorrect - **Option A (Oral penicillin V + outpatient follow-up):** Oral antibiotics do not achieve therapeutic concentrations in infected prosthetic valve tissue. PVE mandates IV therapy and inpatient management. Outpatient follow-up in 4 weeks is dangerously delayed. - **Option B (Warfarin monotherapy):** Anticoagulation treats thrombosis, not infection. Withholding antibiotics in active endocarditis will result in progressive valve destruction, septic emboli, and death. - **Option D (IV ceftriaxone + gentamicin for 6 weeks, medical management):** While this is the correct antibiotic regimen, **medical management alone is insufficient** given the 14 mm vegetation AND paravalvular regurgitation — both are Class I surgical indications. Surgery must precede (or be concurrent with) the antibiotic course, not deferred. ## High-Yield Summary **PVE Mnemonic — "PVE = Surgery First":** - Prosthetic valve + vegetation ≥ 10 mm → Surgery - Paravalvular regurgitation/abscess → Surgery - Fungal or resistant organism → Surgery - Hemodynamic instability → Emergency surgery **Reference:** Habib G et al. 2023 ESC Guidelines for the management of endocarditis. *European Heart Journal*; Harrison's Principles of Internal Medicine, 21st ed., Chapter on Infective Endocarditis.